Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
24/03/2026
UAE Ministry of Defense: UAE Air Defense intercepted 5 ballistic missiles and 17 drones.
Latest
3 m ago
According to a research report released by Open Source Securities on March 24th, Dana Bio (920009.SH) was given a "buy" rating. The main reasons for the rating include: 1) The company's early diagnosis specialty in invasive fungal diseases has a market share of over 30%; 2) The expanding demand for in vitro diagnostics, with the Chinese pathogenic microorganism diagnostic market expected to exceed one billion yuan by 2030; 3) The mortality rate of invasive fungal diseases is 27.6% and early diagnosis is crucial; 4) Dana Bio has two exclusive domestic products, a total of 91 domestic patents, and is involved in 10 major technology projects. (Daily Economic News)
4 m ago
Total will shift $1 billion in investments from wind power projects to a liquefied natural gas project in Texas.
4 m ago
Zhu Hexin met with Alexander Evans, CEO of HSBC Group.
4 m ago
Every AI's flash news, Cinda Securities announced on March 24th that it has given Baiyunshan (600332.SH) a "buy" rating in its research report. The main reasons for the rating include: 1) outstanding performance on the income side & pressure on pharmaceutical products, short-term pressure on 25Q4 quarterly profits; 2) comprehensive deployment of "internationalization + research and development innovation + external development + market value management". (Daily Economic News)
4 m ago
Agile Robotics Company has reached a partnership with Google DeepMind to inject intelligent capabilities into the field of robotics.
See all latest